Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Fighting Resistant Bacteria with Antimicrobial Peptides

Project description

Firing back at superbugs with antimicrobial peptides

Antimicrobial resistance is a growing global-health crisis, driving the need for alternatives to conventional antibiotics. Antimicrobial peptides (AMPs), developed under the ERC-funded Peptide Killers of Bacteria project, have emerged as strong candidates. They demonstrate potent nanomolar activity against bacteria with low cytotoxicity to human cells. TThis ERC-funded FireBacteria project will evaluate the pharmacokinetics, stability, and ADMET profiles of AMPs, as well as their activity against a broader spectrum of bacterial strains. Preclinical studies in murine models will be expanded to include new infection sites and administration routes. The project also aims to assess market needs, secure IP rights, and outline a clinical development strategy.

Objective

"Antimicrobial resistance (AMR) is a critical global health threat, associated with approximately 5 million deaths annually and a severe economic burden. To combat this threat, this project aims to advance the development of our de novo designed antimicrobial peptides (AMPs) towards novel therapeutics. These AMPs, developed within our ERC Consolidator project ""Peptide Killers of Bacteria"", utilize a mechanism distinct from traditional antibiotics, namely the disruption of bacterial cell membranes. This potentially novel class of antibiotics has already achieved nanomolar antibacterial activity, while exhibiting low toxicity to human cells in our in vitro tests. The susceptible bacteria include antibiotic-resistant strains of the Gram-negative A. baumannii, K. pneumoniae, and P. aeruginosa, which are on the CDC's and WHO's list of priority pathogens. Within this project, we aim to perform key preclinical tests with our AMPs. Our goal is five-fold: [1] determine the activity spectrum against genetically diverse bacterial species and strains; [2] evaluate the stability and efficacy of our AMPs in biological fluids, as well as their ADMET properties; [3] expand the scope of our preliminary in vivo data with murine models to include an additional administration route and infected sites; [4] analyze the prevalence and incidence of target infections to better understand the market size and societal impact; and [5] investigate the market potential, secure intellectual property rights, and develop a business strategy for clinical development. Successful implementation of this project will pave the way for future clinical testing and development of our AMPs, which could lead to effective treatments for the emerging AMR crisis of antibiotic-resistant infections."

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

Masarykova univerzita
Net EU contribution
€ 150 000,00
Address
Zerotinovo namesti 9
601 77 Brno
Czechia
Region
Česko Jihovýchod Jihomoravský kraj
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)